Modvigil 200mg Review: Evidence, Safety & Australia

Medical Disclaimer

This modvigil 200mg review provides general educational information and is not personalised medical advice. It should not be used to self-prescribe, choose a dose or change a prescription medicine. Individual suitability, dosing and treatment decisions require appropriate healthcare guidance.

A useful modvigil 200mg review should do more than repeat claims about modafinil or collect favourable online comments. It should separate what is known about the Modvigil product, what comes from clinical evidence about the active ingredient modafinil, and what Australian regulatory sources can establish about a specific therapeutic good. Those distinctions matter because evidence at one level does not automatically prove claims at another.

Modvigil is a branded product associated with modafinil, while modafinil is the active pharmaceutical ingredient linked with it. Clinical evidence about modafinil can explain its wakefulness-promoting medical role and safety context, but it does not automatically establish the quality, bioequivalence, manufacturing consistency or Australian regulatory status of every product sold under the Modvigil name.

Australian readers also need to distinguish Modvigil from the similarly named MODAVIGIL. The TGA currently lists MODAVIGIL modafinil 100 mg tablet blister pack under ARTG ID 168497. Its current record identifies modafinil as the ingredient, Neuraxpharm Australia Pty Ltd as sponsor and the licence status as active. That regulatory record applies to MODAVIGIL, not Modvigil.

Modvigil 200mg Review at a Glance

Review point	What readers should know
Product	Modvigil / Modvigil-200
Product association	Indian government intellectual-property records associate the MODVIGIL and MODVIGIL-200 labels with HAB Pharmaceuticals & Research Ltd
Stated active ingredient	Modafinil, based on the marketed product presentation and available product labelling; the exact product should still be checked against current documentation
Stated strength	200 mg per tablet for the Modvigil-200 presentation, based on available product labelling
Product type	Branded modafinil product
Medicine context	Modafinil has an established prescription-medicine role as a wakefulness-promoting medicine
Australian scheduling	Modafinil remains in Schedule 4 of Australia’s current scheduling framework
ARTG status	Schedule 4 status does not establish that Modvigil itself is included in the ARTG
Main review limitation	Established clinical evidence mainly concerns modafinil as an active ingredient rather than Modvigil as a specific commercial product

A responsible modvigil 200mg review therefore needs to distinguish the evidence supporting the label, the evidence supporting the active ingredient and the evidence supporting Australian regulatory claims.

Official Indian intellectual-property records provide useful product-identity evidence. A December 2023 register entry identifies “MODVIGIL-200 (LABEL)” as an artistic work associated with HAB Pharmaceuticals and Research Ltd, while an earlier application register also lists MODVIGIL and MODVIGIL-200 labels under that company. These records establish a brand or label association; they do not independently establish tablet composition, manufacturing quality, bioequivalence, GMP compliance or Australian registration.

Available product imagery provides a separate type of evidence. A photographed Modvigil-200 blister states “Modafinil Tablets USP” and “Each uncoated tablet contains Modafinil USP 200 mg”. That supports the stated ingredient and strength of the pictured presentation, but it does not convert an IP record into formulation evidence or prove that every product offered under the name is authentic.

What Is Modvigil 200mg?

Modvigil, including the Modvigil-200 name, is presented as a branded tablet product containing modafinil. Available product labelling identifies the Modvigil-200 presentation as containing 200 mg of modafinil per tablet.

That description needs context. Product identity and clinical evidence are not the same thing.

First, Modvigil-specific evidence concerns the commercial product itself. This includes the brand name, current labelling, stated ingredient and strength, manufacturer association, packaging and formulation details. Each of those claims requires evidence relating to Modvigil.

Second, modafinil evidence concerns the active ingredient. It includes pharmacology, recognised medical uses, pharmacokinetics, contraindications, interactions, warnings and adverse effects. Those findings can explain the medical context of a genuine modafinil-containing product, but they are not automatically clinical evidence about Modvigil.

Third, Australian regulatory evidence concerns matters such as scheduling, ARTG entries and Australian Product Information. Those sources apply according to the substance or specific therapeutic good they identify.

For this modvigil 200mg review, keeping those three evidence levels separate is essential. Otherwise, strong clinical evidence about modafinil can easily be used to fill gaps in what is actually known about a particular branded product

What Does Modvigil 200mg Contain?

Available Modvigil-200 labelling states that each uncoated tablet contains modafinil USP 200 mg. That product-specific label evidence is stronger support for the stated ingredient and strength than the Indian intellectual-property records, which establish only a label association.

The distinction matters because different sources answer different questions.

The Indian copyright records link MODVIGIL and MODVIGIL-200 labels with HAB Pharmaceuticals & Research Ltd. They do not independently prove what is inside a tablet.

By contrast, the available blister labelling explicitly identifies modafinil and 200 mg. Even so, a photographed or marketed product label cannot establish the authenticity or pharmaceutical quality of every tablet offered under the same name.

Where current product documentation confirms 200 mg of modafinil per tablet, that number describes tablet strength. It does not establish an appropriate dose for an individual.

Tablet strength and prescribed dose are different concepts. A commercially produced strength does not tell a reader what amount, if any, is medically appropriate for them.

Likewise, formulation details beyond the supported labelling should not be copied from other modafinil products. Excipients and other product-specific characteristics can differ between brands.

How Does Modvigil Relate to Modafinil?

The simplest relationship is:

Modvigil is the branded product.

Modafinil is the active ingredient associated with it.

That distinction is central to interpreting research and is explored separately in Modvigil 200mg vs modafinil.

If researchers investigate modafinil, their study can provide evidence about modafinil. Unless they specifically studied Modvigil, however, the findings should not be described as a Modvigil clinical trial.

In other words:

A clinical study of modafinil is not automatically a clinical study of Modvigil.

The same principle applies to Australian regulatory records. Australia has ARTG-registered medicines containing modafinil, including MODAVIGIL and several other named products. Their existence establishes a recognised regulatory and medical context for modafinil, but it does not transfer those products’ registrations, sponsors, formulations or quality assessments to Modvigil.

What Can Modafinil Evidence Tell Us About Modvigil 200mg?

Modafinil has an established medical context as a wakefulness-promoting medicine. Australian regulatory records confirm that registered medicines containing modafinil remain on the ARTG.

In a modvigil 200mg review, that ingredient-level evidence is useful because it explains the medical context of modafinil rather than treating the substance as an unfamiliar online compound.

However, it has clear limits.

Research on modafinil does not, by itself, establish:

that every Modvigil tablet contains the labelled amount of modafinil;
that Modvigil is bioequivalent to MODAVIGIL or another Australian product;
that every batch has identical manufacturing characteristics;
that Australian regulators have assessed Modvigil in the same way as an ARTG-registered product;
that Modvigil is clinically superior or inferior to another modafinil brand;
that a particular product supplied under the Modvigil name is authentic.

This evidence boundary is one of the most important parts of the review. Ingredient-level science can be substantial while public brand-specific evidence remains much narrower.

What Effects Are Relevant to a Review of Modvigil 200mg?

The most defensible effect claims come from what reliable sources say about modafinil.

Modafinil is used medically to promote wakefulness in defined sleep-related clinical settings. The TGA describes modafinil as a Schedule 4 prescription-only medicine and warns against treating it as an informal “smart drug” or lifestyle product.

That distinction matters because online descriptions sometimes move from “wakefulness” to much broader claims about intelligence, motivation, studying, memory or exceptional productivity. Those concepts are not interchangeable.

Feeling more awake also does not prove better judgement, learning, memory or overall performance.

For this reason, Modvigil should remain within a prescription-medicine context. A product review should not promote it as a routine consumer tool for studying, gaming, working all night or increasing lifestyle productivity.

For the broader ingredient-level medical context, see Modvigil 200mg uses, benefits and side effects.

How Quickly Can Modafinil Act and How Long Can Its Effects Last?

Timing deserves only concise treatment here because pharmacokinetics and subjective experience are different.

After oral administration, the body absorbs modafinil and later eliminates it. However, the point at which a person notices a change in wakefulness does not necessarily correspond to a single pharmacokinetic measurement.

Food, physiology, other medicines, health conditions and the clinical reason for treatment can also influence how an individual experiences the medicine.

Consequently, this review does not promise that Modvigil will begin working after an exact number of minutes or produce a fixed number of hours of subjective alertness.

Readers should treat highly precise onset and duration claims from testimonials cautiously unless the source and clinical context are clear. The timing distinction is covered in more detail in how long Modvigil 200mg takes to work.

Modvigil 200mg Review Main Advantages and Limitations

A balanced modvigil 200mg review should identify what supports a reasonable product assessment while making the remaining uncertainty visible.

Potential Positives

One useful feature is the product’s identifiable commercial presentation. Indian government records associate the MODVIGIL and MODVIGIL-200 labels with HAB Pharmaceuticals & Research Ltd, while available blister labelling separately identifies the Modvigil-200 presentation as modafinil 200 mg.

In addition, modafinil itself has a substantial medical and regulatory evidence base. Authoritative sources can therefore provide context for its prescription-medicine role, warnings and broader safety profile.

That is more informative than assessing a product associated with an unfamiliar substance that has little clinical documentation.

However, these positives concern an identifiable commercial presentation and an active ingredient with an established medical evidence base. They do not prove that Modvigil has undergone the same product-specific assessment as an Australian-registered modafinil medicine.

Important Limitations

The largest limitation is the gap between modafinil evidence and Modvigil-specific evidence.

A well-studied active ingredient does not remove the need for product-level evidence. Ingredient research cannot independently verify a specific tablet’s manufacturing consistency, authenticity or bioequivalence with another medicine.

This is why a modvigil 200mg review should avoid turning evidence about modafinil into unsupported claims about Modvigil itself.

Individual response creates another limitation. Even where a product contains the expected active ingredient, effects and adverse reactions can vary between patients.

Regulatory status also requires precision. A similarly named product or another medicine containing modafinil cannot establish Modvigil’s Australian status.

Consideration	Review interpretation
MODVIGIL/MODVIGIL-200 label identity	Supported by Indian intellectual-property records
HAB product association	Supported at the label/brand level
Stated modafinil ingredient	Supported by available Modvigil-200 product labelling
200 mg presentation	Supported by available Modvigil-200 labelling; tablet strength is not an individual dosing recommendation
Modafinil clinical evidence	Substantial ingredient-level medical context exists
Modvigil-specific clinical evidence	Should not be assumed from general modafinil research
Australian regulatory status	Requires evidence for the exact therapeutic good
Online testimonials	Anecdotal; they do not establish efficacy, pharmaceutical quality, authenticity, safety or bioequivalence

What About Modvigil 200mg Side Effects?

Any safety discussion begins with authoritative information about modafinil rather than anonymous reports about a particular brand.

Modafinil has recognised adverse effects, warnings, contraindications and medicine interactions. The TGA has previously highlighted the need for medical oversight and has warned consumers about risks associated with obtaining prescription-only modafinil outside appropriate healthcare channels.

This product review does not need to reproduce a complete adverse-effects guide. Instead, the key point is that a modafinil-containing medicine should not be considered risk-free because some users report positive experiences.

One person’s tolerance cannot establish safety for someone else.

Likewise, an online article cannot account for an individual’s medical history, concurrent medicines, allergies, pregnancy status or other prescribing considerations. Those questions require appropriate healthcare guidance.

For a fuller safety discussion, see Modvigil 200mg side effects.

Is Modvigil the Same as MODAVIGIL?

No. Modvigil and MODAVIGIL are separate product names.

The similarity matters in Australia because MODAVIGIL has its own ARTG record.

The current TGA record lists MODAVIGIL modafinil 100mg tablet blister pack, ARTG ID 168497, as a registered medicine. It identifies modafinil as the ingredient, Neuraxpharm Australia Pty Ltd as the sponsor and shows licence status A.

That information applies to MODAVIGIL.

It does not establish the registration, sponsor, formulation, manufacturing quality or regulatory assessment of Modvigil.

The TGA also has an older cancellation record for a different MODAVIGIL entry, ARTG 82350, previously sponsored by CSL Limited. That older cancellation must not be confused with the currently listed ARTG 168497 record.

Two products may share the same active ingredient while differing in product name, sponsor, strength, formulation, regulatory history and market status.

Therefore:

MODAVIGIL’s ARTG record must not be transferred to Modvigil.

Modvigil 200mg Review for Australian Readers

For an Australian modvigil 200mg review, scheduling and product registration need to remain separate regulatory questions.

The Federal Register shows that the Therapeutic Goods (Poisons Standard—June 2026) Instrument applied only through 30 September 2026 and identifies the replacement Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, F2026L01327, registered on 30 September 2026. The October instrument is therefore the relevant current instrument rather than the superseded June edition.

Modafinil remains classified in Schedule 4. The preceding instrument placed MODAFINIL in Schedule 4, headed “Prescription only medicines and prescription animal remedies”, and the TGA’s published October 2026 implementation changes did not identify any rescheduling of modafinil. The TGA also continues to describe modafinil as a Schedule 4 prescription-only medicine.

Accordingly, the durable reader-facing point is:

The current Australian Poisons Standard lists modafinil in Schedule 4.

The TGA explains that the Poisons Standard provides national scheduling classifications for medicines and poisons for incorporation into relevant state and territory legislation. It is therefore more precise to describe Schedule 4 as part of Australia’s scheduling framework rather than implying that one Commonwealth instrument alone describes every practical prescribing and supply rule in every jurisdiction.

Schedule 4 status tells readers something about modafinil as a scheduled substance.

It does not prove that Modvigil is ARTG-registered.

ARTG registration concerns a particular therapeutic good. Product name, sponsor, formulation and the applicable ARTG record therefore matter. The TGA describes the ARTG as its public database of therapeutic goods approved for supply in Australia.

Current TGA records readily identify MODAVIGIL and other named modafinil products. The authoritative material reviewed for this article did not establish an ARTG entry under the exact Modvigil or Modvigil-200 name. However, a search result alone is not sufficient evidence for an absolute statement that an entry cannot exist.

For that reason, this article does not describe Modvigil as “TGA approved” or “ARTG registered”, and it also avoids an unsupported categorical claim that no registration exists.

In a modvigil 200mg review, the practical Australian distinction is therefore:

Schedule 4 status concerns modafinil within Australia’s scheduling framework.

ARTG registration concerns a specific therapeutic good.

Consequently:

Modafinil being Schedule 4 does not prove that Modvigil is ARTG-registered.

What Should You Consider Before Relying on a Modvigil 200mg Review?

Before relying on a modvigil 200mg review, ask what each claim actually proves.

If an article says “studies show Modvigil works”, check whether researchers studied Modvigil itself or modafinil generally.

If a page says the product is “approved”, identify the regulator and the exact therapeutic good named in the record.

Likewise, if a reviewer describes one modafinil brand as stronger or more effective than another, look for controlled comparative evidence rather than assuming a subjective experience proves a clinical difference.

Several useful rules follow:

A clinical study of modafinil is not automatically a clinical study of Modvigil.

An ARTG record for MODAVIGIL is not an ARTG record for Modvigil.

A product label can support a stated ingredient and strength, but it does not prove the authenticity of every product sold under that name.

A testimonial cannot establish pharmaceutical quality or bioequivalence.

Price does not establish medical suitability.

Online experiences can still describe what individual users report. However, sleep patterns, expectations, other medicines, health conditions and product authenticity can all affect those reports.

For this reason, testimonials should remain anecdotes rather than evidence of consistent efficacy, safety or pharmaceutical quality.

For readers considering commercial claims, what to check before ordering Modvigil 200mg online covers product identity, provenance and regulatory checks in more detail.

Who Should Be Cautious About Drawing Conclusions From Online Reviews?

Anyone making a prescription-medicine decision should avoid using online reviews as a substitute for individual clinical assessment.

A reviewer usually does not know a reader’s medical history, other medicines, cardiovascular history, psychiatric history, allergies, pregnancy status or the underlying cause of excessive sleepiness.

Likewise, comments such as “it worked well for me” or “I had no side effects” provide little evidence about another person’s likely response.

A review can clarify product identity, evidence quality and Australian regulatory distinctions. It cannot determine whether modafinil is medically appropriate for a particular reader.

Frequently Asked Questions

What is Modvigil 200mg?

Modvigil-200 is a branded product presented as a modafinil tablet in a 200 mg strength. Indian government records associate the MODVIGIL-200 label with HAB Pharmaceuticals & Research Ltd, while available product labelling separately states modafinil 200 mg. These sources answer different questions and should not be treated as interchangeable.

What is the active ingredient in Modvigil-200?

Available Modvigil-200 blister labelling states that each tablet contains modafinil USP 200 mg. This supports the stated product presentation; it does not independently establish the contents or authenticity of every pack sold under the Modvigil name.

Is Modvigil 200mg the same as modafinil?

Not exactly. Modvigil is a commercial product name, while modafinil is the active pharmaceutical ingredient associated with it. Research on modafinil provides ingredient-level evidence and should not automatically be presented as Modvigil-specific research.

Is Modvigil the same as MODAVIGIL?

No. MODAVIGIL is a separate product with an active Australian ARTG record. The TGA lists MODAVIGIL modafinil 100 mg under ARTG ID 168497, sponsored by Neuraxpharm Australia Pty Ltd. That record applies to MODAVIGIL and should not be transferred to Modvigil.

How long can modafinil-related effects last?

There is no single subjective duration that can be guaranteed for every person. Pharmacokinetic information describes how modafinil behaves in the body, while perceived wakefulness can vary between individuals. Exact timing should therefore not be inferred from testimonials.

What should a modvigil 200mg review tell Australian readers?

A useful modvigil 200mg review should explain that modafinil is currently a Schedule 4 substance in Australia’s scheduling framework while ARTG registration remains product-specific. It should also make clear that the active ARTG record for MODAVIGIL does not establish Modvigil’s regulatory status.

Can an online review determine whether Modvigil is suitable for someone?

No. A review can explain product claims, ingredient-level evidence and regulatory context, but it cannot assess personal medical suitability. Treatment and dosing decisions require appropriate healthcare guidance.

Modvigil 200mg Review Overall Takeaway

The main conclusion from this modvigil 200mg review is that Modvigil should be evaluated at several separate evidence levels rather than treated as synonymous with modafinil itself.

Official Indian records associate the MODVIGIL and MODVIGIL-200 labels with HAB Pharmaceuticals & Research Ltd. Separately, available Modvigil-200 labelling states that the product contains modafinil 200 mg. The label evidence supports the stated product presentation, while the intellectual-property records support the brand association; neither should be asked to prove more than it actually establishes.

Modafinil, by contrast, has an established clinical and Australian regulatory evidence base as a prescription medicine. That evidence can explain the active ingredient’s medical role and safety context, but it cannot automatically serve as Modvigil-specific clinical evidence.

Australian readers must also keep scheduling and ARTG registration separate. The June 2026 Poisons Standard ceased to be the operative edition after 30 September 2026 and was replaced by the October 2026 instrument. Modafinil remains Schedule 4, while ARTG registration continues to apply to individual therapeutic goods.

ModvigilAUS Medical Editorial Team

ModvigilAUS Health Research Desk is the internal editorial team behind ModvigilAUS.com's educational content on Modafinil and Armodafinil. All articles are prepared using publicly available medical and scientific references, Australian regulatory guidance, and internal editorial review standards.

See all author post

Modvigil 200mg Review: What Users Should Know Before Buying